Objective: The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy of type 1 diabetes mellitus reduces the risk of development and progression of microvascular complications. The Epidemiology of Diabetes Interventions and Complications (EDIC) study assessed whether these benefits persisted after the end of DCCT. Results for the adolescent DCCT cohort are reported here. Study design: Of the DCCT adolescent cohort (n = 195), 175 participated in EDIC, 151 had fundus photography, and 156 had albumin excretion rate measured at year 3 or 4. The odds of progression of retinopathy and albuminuria from closeout of the DCCT until EDIC year 4 were assessed. Results: In contrast to the 7.4 years of the DCCT, during which mean hemoglobin A1c levels were significantly lower with intensive therapy than conventional therapy (8.06% vs 9.76%; P < .0001), the subsequent first 4 years of EDIC had mean hemoglobin A1c levels that were similar between the former intensive and the former conventional groups (8.38% vs 8.45%). However, the prevalence of worsening of 3 steps or more in retinopathy and of progression to proliferative or severe nonproliferative retinopathy were reduced by 74% (P < .001) and 78% (P < .007), respectively, in the former intensive therapy group compared with the former conventional group. Conclusions: These findings provide further support for the DCCT recommendation that most adolescents with type 1 diabetes receive intensive therapy aimed at achieving glycemic control as close to normal as possible to reduce the risk of microvascular complications.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of Pediatrics|
|State||Published - 2001|
Bibliographical noteFunding Information:
Supported research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institutes of Health. Additional support was provided by the National Center for Research Resources, through the General Clinical Research Center program, and by Genentech, Inc, through a Cooperative Research and Development Agreement with the NIDDK. Submitted for publication Feb 12, 2001; revision received June 20, 2001; accepted July 17, 2001. Reprint requests: The EDIC Research Group, Box NDIC/EDIC, Bethesda, MD 20892. Copyright © 2001 by Mosby, Inc. 0022-3476/2001/$35.00 + 0 9/21/118887 doi:10.1067/mpd.2001.118887
Copyright © 2001 by Mosby, Inc.